Companies: 10,795·Total market cap: $144.5T
Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc.

MLYSNASDAQHealthcare● Active
$22.86
$-0.83(-3.50%)
Market Cap$1.5B
P/E Ratio
52W High$47.65
52W Low$12.59
SEC Filings

Mineralys Therapeutics, Inc. (MLYS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001933414 · MLYS · NASDAQ · as of Jun 8, 2026

Filing snapshot

353
Total Filings
8-K
Latest Form
2026-06-03
Most Recent
2023
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001933414 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-12
Fiscal Year End
Mar 12, 2026
Accession No.
0001933414-26-000056
Primary Document
mlys-20251231.htm
Source: data.sec.gov · CIK 0001933414 · Accession 0001933414-26-000056

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-06
8-KCurrent Report
8-K
2026-06-03Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-03
View
424B5424B5
424B5
2026-06-03
View
8-KCurrent Report
8-K
2026-06-03
View
8-KCurrent Report
8-K
2026-05-22
View
10-QQuarterly Report
10-Q
2026-05-06
View
8-KCurrent Report
8-K
2026-05-06
View
ARSARS
ARS
2026-04-10
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-08
View
DEF 14AProxy Statement
DEF 14A
2026-04-08
View
10-KAnnual Report
10-K
2026-03-12
View
8-KCurrent Report
8-K
2026-03-12
View
8-KCurrent Report
8-K
2026-03-09
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-03-04
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-13
View
S-8Employee Stock Plan Registration
S-8
2026-02-13
View
Showing 1–15 of 141 filingsForm 4 / 144 hidden· 353 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001933414  |  Exchange: NASDAQ · Healthcare

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has submitted 353 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2023. As a Healthcare sector company with CIK 0001933414, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Mineralys Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Mineralys Therapeutics, Inc. 10-K was filed on 2026-03-12 for fiscal year ending 2026. Historical MLYS 10-K annual reports are available from 2022 through 2026.

Investors researching Mineralys Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

MLYS SEC Filings · 8 questions

Mineralys Therapeutics, Inc. (MLYS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 353 filings and access original documents at no cost. Mineralys Therapeutics, Inc.'s CIK is 0001933414.

MLYS SEC filingsMineralys Therapeutics, Inc. SEC documentsfind MLYS 10-K